Analysts’ Weekly Ratings Updates for Regeneron Pharmaceuticals (REGN)

Several brokerages have updated their recommendations and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) in the last few weeks:

  • 12/15/2018 – Regeneron Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 12/13/2018 – Regeneron Pharmaceuticals was upgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “conviction-buy” rating.
  • 12/11/2018 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/7/2018 – Regeneron Pharmaceuticals was given a new $483.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 12/2/2018 – Regeneron Pharmaceuticals was given a new $440.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/23/2018 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/16/2018 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 11/13/2018 – Regeneron Pharmaceuticals was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 11/13/2018 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Argus.
  • 11/7/2018 – Regeneron Pharmaceuticals was given a new $405.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “hold” rating on the stock. They wrote, “REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral.””
  • 11/6/2018 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $385.00 price target on the stock.
  • 10/31/2018 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/22/2018 – Regeneron Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald to $441.00. They now have a “neutral” rating on the stock.
  • 10/22/2018 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $385.00 price target on the stock.
  • 10/22/2018 – Regeneron Pharmaceuticals was given a new $405.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “hold” rating on the stock.
  • 10/19/2018 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of NASDAQ:REGN traded down $5.67 during midday trading on Monday, hitting $375.50. 833,090 shares of the stock were exchanged, compared to its average volume of 832,626. The company has a current ratio of 4.04, a quick ratio of 3.30 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals Inc has a 52-week low of $281.89 and a 52-week high of $416.49. The firm has a market cap of $41.25 billion, a price-to-earnings ratio of 28.00, a P/E/G ratio of 1.68 and a beta of 1.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The business had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period last year, the company earned $3.99 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 18.88 EPS for the current year.

In related news, Director Michael S. Brown sold 2,000 shares of the stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total transaction of $784,520.00. Following the completion of the sale, the director now directly owns 2,000 shares in the company, valued at $784,520. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 4,006 shares of company stock valued at $1,564,114. 12.42% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in REGN. Rehmann Capital Advisory Group raised its holdings in Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 68 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 4.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 141 shares in the last quarter. Cito Capital Group LLC raised its holdings in Regeneron Pharmaceuticals by 4.3% during the third quarter. Cito Capital Group LLC now owns 3,650 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 150 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 1.3% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,325 shares of the biopharmaceutical company’s stock valued at $4,252,000 after buying an additional 153 shares in the last quarter. Finally, HPM Partners LLC raised its holdings in Regeneron Pharmaceuticals by 3.4% during the third quarter. HPM Partners LLC now owns 4,744 shares of the biopharmaceutical company’s stock valued at $1,917,000 after buying an additional 157 shares in the last quarter. Institutional investors and hedge funds own 67.21% of the company’s stock.

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: How does a reverse stock split work?

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply